These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2467015)

  • 1. The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia.
    Weber JP; Oesterling JE; Peters CA; Partin AW; Chan DW; Walsh PC
    J Urol; 1989 Apr; 141(4):987-92. PubMed ID: 2467015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia.
    Peters CA; Walsh PC
    N Engl J Med; 1987 Sep; 317(10):599-604. PubMed ID: 2441256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men.
    Weber JP; Walsh PC; Peters CA; Spivak JL
    Am J Hematol; 1991 Mar; 36(3):190-4. PubMed ID: 1705094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum prostate-antigen levels in patients with benign prostatic hypertrophy treated with leuprolide.
    Levine AC; Kirschenbaum A; Kaplan P; Droller MA; Gabrilove JL
    Urology; 1989 Jul; 34(1):10-3. PubMed ID: 2473567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of prostate volume, prostate-specific antigen, and testosterone to flutamide in men with benign prostatic hyperplasia.
    Stone NN; Clejan SJ
    J Androl; 1991; 12(6):376-80. PubMed ID: 1722793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the addition of estrogen to medical castration on prostatic size, symptoms, histology and serum prostate specific antigen in 4 men with benign prostatic hypertrophy.
    Levine AC; Kirschenbaum A; Droller M; Gabrilove JL
    J Urol; 1991 Sep; 146(3):790-3. PubMed ID: 1714969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
    Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z
    J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
    Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
    Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.
    Marberger M; Roehrborn CG; Marks LS; Wilson T; Rittmaster RS
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1323-8. PubMed ID: 16434455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men.
    Liu CC; Huang SP; Li WM; Wang CJ; Chou YH; Li CC; Huang CH; Wu WJ
    Urology; 2007 Oct; 70(4):677-80. PubMed ID: 17991536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
    Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
    J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of long-acting gonadotropin-releasing hormone analog (leuprolide) therapy on prostatic size and symptoms in 15 men with benign prostatic hypertrophy.
    Gabrilove JL; Levine AC; Kirschenbaum A; Droller M
    J Clin Endocrinol Metab; 1989 Sep; 69(3):629-32. PubMed ID: 2474565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
    Bong GW; Clarke HS; Hancock WC; Keane TE
    Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin).
    Andreyko JL; Monroe SE; Jaffe RB
    J Clin Endocrinol Metab; 1986 Oct; 63(4):854-9. PubMed ID: 2943756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia.
    Noguchi K; Suzuki K; Teranishi J; Kondo K; Kishida T; Saito K; Uemura H; Kubota Y
    Hinyokika Kiyo; 2006 Jul; 52(7):527-30. PubMed ID: 16910584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Association of Polymorphisms in the Gene Encoding Gonadotropin-Releasing Hormone with Serum Testosterone Level during Androgen Deprivation Therapy and Prognosis of Metastatic Prostate Cancer.
    Shiota M; Fujimoto N; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Yokomizo A; Kajioka S; Uchiumi T; Eto M
    J Urol; 2018 Mar; 199(3):734-740. PubMed ID: 28941922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
    Tombal B; Cornel EB; Persad R; Stari A; Gómez Veiga F; Schulman C
    J Urol; 2017 Nov; 198(5):1054-1060. PubMed ID: 28552710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of hormone application by subcutaneous injections or steroid-containing silastic implants on human benign hyperplastic prostate tissue transplanted into male nude mice.
    Claus S; Aumüller G; Tunn S; Senge T; Schulze H
    Prostate; 1993; 22(3):199-215. PubMed ID: 7683815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.